The Oligonucleotides & Peptides World Asia Congress 2026 is the region’s leading platform dedicated to advancing oligonucleotide and peptide-based therapeutics across the value chain — from early-stage R&D and clinical trials to large-scale manufacturing.
As Asia emerges as a key hub for next-generation therapeutics, the Congress will bring together leaders from biopharma and big pharma, alongside regulatory experts, to exchange insights, explore innovation, and strengthen regional collaboration. Through a carefully curated programme featuring case studies from across APAC, the Congress aims to accelerate development pipelines and drive manufacturing excellence in oligonucleotide and peptide therapies.
Spanning eight focused sessions, the Oligonucleotides & Peptides World Asia Congress 2026 will explore the latest advancements in ASOs, siRNA, and peptide therapeutics; innovative delivery and formulation technologies; and progress in clinical trials and translational research across the region. The programme will also address scalable manufacturing, evolving regulatory frameworks, emerging digital and platform innovations, and best practices in quality and analytical strategies — offering a comprehensive view of Asia’s expanding oligonucleotide and peptide ecosystem, from R&D to large-scale production.
